On Wednesday, Stereotaxis Inc. (NYSE:STXS) said it has entered into a definitive agreement to acquire Robocath, a venture-backed developer of robotic technologies for interventional cardiology and neurointerventions.

Stereotaxis offers surgical robotics for minimally invasive endovascular intervention. This acquisition significantly strengthens Stereotaxis’ capabilities in endovascular procedures.

The acquisition of Robocath is expected to accelerate Stereotaxis’ entry into large interventional markets, which represent tens of billions of dollars in annual revenue.

The strategic move aims to enhance Stereotaxis’ position in the robotic technologies market, potentially driving significant revenue growth as the company integrates Robocath’s solutions into its offerings, which could contribute approximately $2 million in annual revenue in the first year post-acquisition.

The transaction is projected to become breakeven by the third year post-acquisition, supported by commercial and operational synergies.

Expansion Plans And Regulatory Timeline

Stereotaxis plans to accelerate the development of Robocath’s next-generation system and pursue regulatory submissions in the United States and Europe within the next two years.

The combined platform will integrate the robotic systems of Robocath and Stereotaxis to offer a seamless joint solution in interventional cardiology and neurointerventions.

Future developments are expected to expand applications into Electrophysiology.

The transaction consideration includes an upfront payment of $20 million, and additional contingent payments of up to $25 million tied to regulatory and commercial milestones. The acquisition is expected to close in mid-2026.

At December 31, 2025, Stereotaxis had cash and cash equivalents of $13.4 million and no debt. 

Technical Analysis

Stereotaxis is currently trading within its 52-week range, with a high of $3.59 and a low of $1.67, indicating it is positioned closer to the lower end of this range.

The stock is trading 8.4% above its 20-day simple moving average (SMA) and 1.5% above its 50-day SMA, suggesting a short-term bullish trend while still facing resistance from the longer-term 100-day and 200-day SMAs, which it is trading 8.9% and 17.8% below, respectively.

The relative strength index (RSI) is at 57.91, indicating a neutral momentum, suggesting that the stock is neither overbought nor oversold at this time.

The moving average convergence divergence (MACD) shows a bullish signal, with the MACD line above the signal line, indicating potential upward momentum in the near term.

  • Key Resistance: $2.50 — A level where selling pressure has historically emerged.
  • Key Support: $1.75 — A level that may provide buying interest if tested.

STXS Stock Price Activity: Stereotaxis shares were up 0.99% at $2.05 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock